These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 26817307

  • 1. [Treatment of castration-resistant prostate cancer: Evidence-based clinical practice].
    Wang W, Peng RX, Shi GW, Chen SY, Ding Q, He JY.
    Zhonghua Nan Ke Xue; 2015 Dec; 21(12):1121-4. PubMed ID: 26817307
    [Abstract] [Full Text] [Related]

  • 2. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
    Benidir T, Hersey K, Finelli A, Hamilton R, Joshua AM, Kulkarni G, Zlotta A, Fleshner N.
    Urol Oncol; 2018 May; 36(5):240.e13-240.e20. PubMed ID: 29454590
    [Abstract] [Full Text] [Related]

  • 3. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015.
    Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS.
    J Urol; 2016 May; 195(5):1444-1452. PubMed ID: 26498056
    [Abstract] [Full Text] [Related]

  • 4. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
    Hernandez RK, Cetin K, Pirolli M, Quigley J, Quach D, Smith P, Stryker S, Liede A.
    Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
    [Abstract] [Full Text] [Related]

  • 5. Castration-resistant prostate cancer: AUA guideline amendment.
    Cookson MS, Lowrance WT, Murad MH, Kibel AS, American Urological Association.
    J Urol; 2015 Feb; 193(2):491-9. PubMed ID: 25444753
    [Abstract] [Full Text] [Related]

  • 6. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [Abstract] [Full Text] [Related]

  • 7. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018.
    Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS.
    J Urol; 2018 Dec; 200(6):1264-1272. PubMed ID: 30086276
    [Abstract] [Full Text] [Related]

  • 8. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A, Small EJ.
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [Abstract] [Full Text] [Related]

  • 9. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [Abstract] [Full Text] [Related]

  • 10. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
    Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Winquist E, Cancer Care Ontario Genitourinary Cancer Disease Site Group.
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
    [Abstract] [Full Text] [Related]

  • 11. [New progress of castration-resistant prostate cancer immunotherapy].
    Liu JP, Wang H.
    Zhonghua Wai Ke Za Zhi; 2016 Oct 01; 54(10):787-791. PubMed ID: 27686644
    [Abstract] [Full Text] [Related]

  • 12. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research.
    Penson DF, Lin DW, Karsh L, Quinn DI, Shevrin DH, Shore N, Symanowski JT, Brown B, Forer D, Wong EK, Flanders SC.
    Future Oncol; 2016 Dec 01; 12(23):2689-2699. PubMed ID: 27528114
    [Abstract] [Full Text] [Related]

  • 13. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
    Akaza H.
    Nihon Rinsho; 2014 Dec 01; 72(12):2108-15. PubMed ID: 25518342
    [Abstract] [Full Text] [Related]

  • 14. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K, Minami T, Nozawa M, Kimura T, Egawa S, Fujimoto H, Yamada A, Itoh K, Uemura H.
    Eur Urol; 2016 Jul 01; 70(1):35-41. PubMed ID: 26782346
    [Abstract] [Full Text] [Related]

  • 15. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.
    Grenader T, Plotkin Y, Gips M, Cherny N, Gabizon A.
    Oncol Rep; 2014 Jan 01; 31(1):428-34. PubMed ID: 24247716
    [Abstract] [Full Text] [Related]

  • 16. [Updated treatment of castration-resistant prostate cancer].
    Xu S, Zhang ZY.
    Zhonghua Nan Ke Xue; 2014 Dec 01; 20(12):1136-40. PubMed ID: 25597184
    [Abstract] [Full Text] [Related]

  • 17. [Updated treatments of castration-resistant prostate cancer].
    Wei YF, Gu XJ, Zhu QY.
    Zhonghua Nan Ke Xue; 2016 May 01; 22(5):455-61. PubMed ID: 27416673
    [Abstract] [Full Text] [Related]

  • 18. Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database.
    Hirst CJ, Cabrera C, Kirby M.
    Cancer Epidemiol; 2012 Dec 01; 36(6):e349-53. PubMed ID: 22910034
    [Abstract] [Full Text] [Related]

  • 19. [Gene therapy for castration resistant prostate cancer].
    Nasu Y.
    Nihon Rinsho; 2014 Dec 01; 72(12):2152-7. PubMed ID: 25518350
    [Abstract] [Full Text] [Related]

  • 20. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
    Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BT, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, Freedland SJ.
    J Urol; 2015 Apr 01; 193(4):1232-8. PubMed ID: 25463986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.